{
  "search_condition": "breast cancer",
  "processing_type": "concurrent_search_and_process",
  "summary": {
    "total_trials": 2,
    "successful_trials": 2,
    "failed_trials": 0,
    "success_rate": 100.0,
    "duration_seconds": 78.05307292938232,
    "processing_rate": 0.02562359078174255
  },
  "task_statistics": {
    "total_tasks": 2,
    "completed_tasks": 2,
    "successful_tasks": 2,
    "failed_tasks": 0,
    "completion_rate": 1.0,
    "success_rate": 1.0,
    "workers_running": 20,
    "queue_size": 0
  },
  "successful_trials": [
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01922921",
          "briefTitle": "Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2014-02-05"
          },
          "completionDateStruct": {
            "date": "2021-09-01"
          }
        },
        "descriptionModule": {
          "briefSummary": "This randomized phase I/II trial studies the side effects of vaccine therapy with or without polysaccharide-K and to see how well it works in treating patients with stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer who are receiving HER2-targeted monoclonal antibody therapy. Vaccines made from HER2 intracellular domain (ICD) peptide may help the body build an effective immune response to kill tumor cells that express HER2. Polysaccharide-K may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether vaccine therapy works better when given with or without polysaccharide-K in treating breast cancer."
        },
        "conditionsModule": {
          "conditions": [
            "HER2/Neu Positive",
            "Recurrent Breast Carcinoma",
            "Stage IV Breast Cancer"
          ]
        }
      },
      "McodeResults": {
        "extracted_entities": [],
        "mcode_mappings": [
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Breast Carcinoma",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Recurrent Breast Carcinoma",
            "mapping_rationale": "Direct statement of cancer diagnosis with recurrence status",
            "id": "17b142dd-79d6-49fb-92dd-7c0dedd87f10"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TNMStage",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tnmstage",
              "display": "TNMStage"
            },
            "value": "Stage IV",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Stage IV Breast Cancer",
            "mapping_rationale": "Explicit staging information for breast cancer",
            "id": "4ed5c524-b910-4964-b231-178de6ef270a"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerRelatedComorbidities",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancerrelatedcomorbidities",
              "display": "CancerRelatedComorbidities"
            },
            "value": "HER2/Neu Positive",
            "mapping_confidence": 1.0,
            "source_text_fragment": "HER2/Neu Positive",
            "mapping_rationale": "Direct statement of HER2 biomarker status",
            "id": "ba5fdb93-742e-41b9-894d-bc5f1f0729a7"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Stage IV HER2 positive breast cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "patients with stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer",
            "mapping_rationale": "Direct statement of cancer diagnosis with specific stage and HER2 status",
            "id": "42e19144-834d-4049-96e7-364e704963fc"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TNMStage",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tnmstage",
              "display": "TNMStage"
            },
            "value": "Stage IV",
            "mapping_confidence": 1.0,
            "source_text_fragment": "stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer",
            "mapping_rationale": "Explicit staging information provided for breast cancer",
            "id": "c718e3c1-66c4-4073-bc54-a273978a7e42"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "HER2ReceptorStatus",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "her2receptorstatus",
              "display": "HER2ReceptorStatus"
            },
            "value": "HER2 positive",
            "mapping_confidence": 1.0,
            "source_text_fragment": "human epidermal growth factor receptor 2 (HER2) positive breast cancer",
            "mapping_rationale": "Direct statement of HER2 receptor status",
            "id": "a3c85757-758f-4757-a472-84ae4ee0f94f"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Vaccine therapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "vaccine therapy with or without polysaccharide-K",
            "mapping_rationale": "Explicit mention of vaccine therapy as treatment modality",
            "id": "28bb3e4f-62e7-46d0-9380-4074327aa960"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Polysaccharide-K",
            "mapping_confidence": 1.0,
            "source_text_fragment": "vaccine therapy with or without polysaccharide-K",
            "mapping_rationale": "Direct mention of polysaccharide-K as potential treatment component",
            "id": "4127b3c2-4c77-40a5-bc05-a67d9b45397f"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "HER2-targeted monoclonal antibody therapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "receiving HER2-targeted monoclonal antibody therapy",
            "mapping_rationale": "Explicit statement of monoclonal antibody therapy targeting HER2",
            "id": "0ff56632-a13a-4b8d-9544-1a70440c9184"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "HER2 intracellular domain (ICD) peptide vaccine",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Vaccines made from HER2 intracellular domain (ICD) peptide",
            "mapping_rationale": "Direct description of vaccine composition using HER2 ICD peptide",
            "id": "8a6b8a2b-388b-47fe-a5eb-f923fc6af6fb"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Breast Cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Stage IV HER2 Positive Breast Cancer",
            "mapping_rationale": "Direct statement of breast cancer diagnosis",
            "id": "db292d88-bf73-4456-b319-929d19f4f4be"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "TNMStage",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "tnmstage",
              "display": "TNMStage"
            },
            "value": "Stage IV",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Stage IV HER2 Positive Breast Cancer",
            "mapping_rationale": "Explicit staging information provided",
            "id": "90418f30-8448-4ff2-911b-5cd4e986292e"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "HER2ReceptorStatus",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "her2receptorstatus",
              "display": "HER2ReceptorStatus"
            },
            "value": "Positive",
            "mapping_confidence": 1.0,
            "source_text_fragment": "HER2 Positive Breast Cancer",
            "mapping_rationale": "Direct statement of HER2 positive status",
            "id": "9f21473d-0d3a-4b4b-a334-7823e75d7c0d"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "HER2-Targeted Monoclonal Antibody Therapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "receiving HER2-Targeted Monoclonal Antibody Therapy",
            "mapping_rationale": "Explicit treatment regimen stated",
            "id": "19e5031f-cb6d-4f75-9146-9810acba6ace"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Vaccine Therapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Vaccine Therapy With or Without Polysaccharide-K",
            "mapping_rationale": "Direct statement of vaccine therapy treatment",
            "id": "e8b0592a-2282-4a43-9eb0-fa951d57bcc2"
          }
        ],
        "source_references": [],
        "validation": {
          "valid": true,
          "errors": [],
          "warnings": [],
          "compliance_score": 1.0
        },
        "metadata": {
          "engine_type": "LLM",
          "entities_count": 0,
          "mapped_count": 15,
          "compliance_score": 1.0,
          "token_usage": {
            "prompt_tokens": 806,
            "completion_tokens": 644,
            "total_tokens": 1450
          },
          "aggregate_token_usage": {
            "prompt_tokens": 1702,
            "completion_tokens": 1592,
            "total_tokens": 3294,
            "model_name": "deepseek-coder",
            "provider_name": "deepseek"
          }
        },
        "error": null
      }
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01026116",
          "briefTitle": "A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old"
        },
        "statusModule": {
          "overallStatus": "COMPLETED",
          "startDateStruct": {
            "date": "2009-12"
          },
          "completionDateStruct": {
            "date": "2016-12-23"
          }
        },
        "descriptionModule": {
          "briefSummary": "Manifold data revealed that young breast cancer patients are characterized by aggressive clinical history. The purpose of this study is to evaluate the efficacy and safety of different strategies incorporating paclitaxel to anthracycline-based regimens in young breast cancer patients."
        },
        "conditionsModule": {
          "conditions": [
            "Breast Neoplasms"
          ]
        }
      },
      "McodeResults": {
        "extracted_entities": [],
        "mcode_mappings": [
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Breast Neoplasms",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Conditions: Breast Neoplasms",
            "mapping_rationale": "Direct, unambiguous statement of cancer condition using standard medical terminology for breast cancer",
            "id": "beded61d-7e17-4861-bdd3-740a26267d82"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "breast cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "young breast cancer patients are characterized by aggressive clinical history",
            "mapping_rationale": "Direct mention of breast cancer diagnosis",
            "id": "85174546-07c1-40a5-a33f-a5a46cc2574c"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Age",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "age",
              "display": "Age"
            },
            "value": "young",
            "mapping_confidence": 0.7,
            "source_text_fragment": "young breast cancer patients are characterized by aggressive clinical history",
            "mapping_rationale": "Explicit mention of young age group, though not specific numeric value",
            "id": "c0c59855-8ac5-496f-8539-f537f6008e3f"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "paclitaxel",
            "mapping_confidence": 1.0,
            "source_text_fragment": "different strategies incorporating paclitaxel to anthracycline-based regimens",
            "mapping_rationale": "Direct mention of paclitaxel as part of treatment regimen",
            "id": "c5a8a058-1792-43ca-a3f4-604d3c905055"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "anthracycline-based regimens",
            "mapping_confidence": 1.0,
            "source_text_fragment": "different strategies incorporating paclitaxel to anthracycline-based regimens",
            "mapping_rationale": "Direct mention of anthracycline-based treatment regimens",
            "id": "a0943860-b9d4-4c60-9fd0-dcbc264ee9d3"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Breast Cancer",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Operable Breast Cancer Patients",
            "mapping_rationale": "Direct mention of breast cancer diagnosis",
            "id": "6d80fe60-c80c-4131-bca1-4c372b4386f8"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "Age",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "age",
              "display": "Age"
            },
            "value": "Less Than 40 Years Old",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Patients Less Than 40 Years Old",
            "mapping_rationale": "Explicit age range specification",
            "id": "758ff6ba-6177-4110-b239-d4ba673c645f"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "EC-wP",
            "mapping_confidence": 0.9,
            "source_text_fragment": "EC-wPversus EP-wP as Adjuvant Therapy",
            "mapping_rationale": "Direct mention of chemotherapy regimen EC-wP",
            "id": "ac68a375-1ad4-4aaa-8ae4-12ec7e97dccd"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "EP-wP",
            "mapping_confidence": 0.9,
            "source_text_fragment": "EC-wPversus EP-wP as Adjuvant Therapy",
            "mapping_rationale": "Direct mention of chemotherapy regimen EP-wP",
            "id": "cfd80553-d74e-451d-942d-b35428bcada6"
          },
          {
            "resourceType": "Observation",
            "mcode_element": "CancerTreatment",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancertreatment",
              "display": "CancerTreatment"
            },
            "value": "Adjuvant Therapy",
            "mapping_confidence": 1.0,
            "source_text_fragment": "as Adjuvant Therapy for Operable Breast Cancer",
            "mapping_rationale": "Explicit mention of adjuvant therapy",
            "id": "332f540f-b438-40d7-b711-f829764b099c"
          },
          {
            "resourceType": "Condition",
            "mcode_element": "CancerCondition",
            "code": {
              "system": "http://hl7.org/fhir/us/mCODE",
              "code": "cancercondition",
              "display": "CancerCondition"
            },
            "value": "Operable",
            "mapping_confidence": 1.0,
            "source_text_fragment": "Operable Breast Cancer Patients",
            "mapping_rationale": "Direct mention of operable status",
            "id": "acf2b21a-116c-4cbb-9771-6c5b457027e4"
          }
        ],
        "source_references": [],
        "validation": {
          "valid": true,
          "errors": [],
          "warnings": [],
          "compliance_score": 1.0
        },
        "metadata": {
          "engine_type": "LLM",
          "entities_count": 0,
          "mapped_count": 11,
          "compliance_score": 1.0,
          "token_usage": {
            "prompt_tokens": 803,
            "completion_tokens": 757,
            "total_tokens": 1560
          },
          "aggregate_token_usage": {
            "prompt_tokens": 0,
            "completion_tokens": 0,
            "total_tokens": 0,
            "model_name": "",
            "provider_name": ""
          }
        },
        "error": null
      }
    }
  ],
  "failed_trials": []
}